Adverse Event Management in HR+/HER2– Advanced Breast Cancer: PI3K/AKT/PTEN Pathway - Episode 2
First-Line Treatment Strategies for HR+/HER2- Advanced Breast Cancer
Panelists discuss how to approach selecting first-line treatment options for hormone receptor–positive, HER2-negative advanced breast cancer by providing an overview of standard-of-care options and highlighting the primary considerations that guide treatment selection.
Video Player is loading.
Video content above is prompted by the following:
- What is your approach to selecting first-line treatment options for hormone receptor–positive, HER2-negative advanced breast cancer? Please provide a high-level overview of standard-of-care treatment options in the first line.
- What are primary considerations in selecting a first-line treatment?
Related Content:
